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Abstract Genome-wide association studies (GWAS)
conducted using commercial single nucleotide polymor-
phisms (SNP) arrays have proven to be a powerful tool for
the detection of common disease susceptibility variants.
However, their utility for the detection of lower frequency
variants is yet to be practically investigated. Here we
describe the application of a rare variant collapsing method
to a large genome-wide SNP dataset, the Wellcome Trust
Case Control Consortium rheumatoid arthritis (RA)
GWAS. We partitioned the data into gene-centric bins and
collapsed genotypes of low frequency variants (deﬁned
here as MAF B0.05) into a single count coupled with
univariate analysis. We then prioritised gene regions for
further investigation in an independent cohort of 3,355
cases and 2,427 controls based on rare variant signal p
value and prior evidence to support involvement in RA. A
total of 14,536 gene bins were investigated in the primary
analysis and signals mapping to the TNFAIP3 and
chr17q24 loci were selected for further investigation. We
detected replicating association to low frequency variants
in the TNFAIP3 gene (combined p = 6.6 9 10
-6). Even
though rare variants are not well-represented and can be
difﬁcult to genotype in GWAS, our study supports the
application of low frequency variant collapsing methods to
genome-wide SNP datasets as a means of exploiting data
that are routinely ignored.
Introduction
Genetic epidemiology of common disease has been trans-
formed by the recent advent of the genome-wide associa-
tion study (GWAS) that allows the unbiased testing of
hundreds of thousands of single nucleotide polymorphisms
(SNPs) in large sample collections. This approach has
greatly accelerated the identiﬁcation of genetic markers
associated with disease susceptibility and continuous traits.
The Catalogue of Published Genome-Wide Association
Studies contains details from 378 published GWAS
reporting 1,700 SNP associations to diseases or quantita-
tive traits (with p\10
-5) to date (Hindorff et al. 2009).
While the GWAS strategy has undoubtedly been suc-
cessful in identifying a multitude of disease-associated
makers, these have been shown to explain very little of the
estimated heritable component of complex disease (Maher
2008). For example, all of the currently known rheumatoid
arthritis (RA) risk alleles, including the major histocom-
patibility complex (MHC) locus, have been estimated to
explain less than half of the total genetic component
(Raychaudhuri et al. 2008), indicating that a substantial
proportion of susceptibility variants remain undiscovered.
The deﬁcit between estimated heritability of a particular
trait and its known genetic variation may be attributed to a
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mary scans are likely to serve only as proxies for the true
causal variant, therefore estimates of their contribution to
genetic risk may be greatly underestimated (McCarthy and
Hirschhorn 2008). Secondly, further variants at an associ-
ated locus may confer additional effects independent of the
primary signal (Plenge et al. 2007). In addition, structural
variation, such as insertions, deletions, and duplications, is
now recognised as a well-established feature of the genome
(Iafrate et al. 2004; Redon et al. 2006; Sebat et al. 2004),
with a number of emerging studies reporting associations
to disease susceptibility (Fanciulli et al. 2007; Fellermann
et al. 2006; Gonzalez et al. 2005; Hollox et al. 2008;
McKinney et al. 2008). Importantly, a signiﬁcant propor-
tion of inherited susceptibility to common disease may be
attributable to the effects of multiple, low frequency vari-
ants with moderate effects in a number of genes (Bodmer
and Bonilla 2008). The majority of variants in the human
genome are predicted to have minor allele frequency
(MAF) below 0.05 and are correlated with increased
functional signiﬁcance (Gorlov et al. 2008). Evidence to
support the involvement of rare variants in the suscepti-
bility to common disease comes from both theoretical
(Pritchard 2001; Pritchard and Cox 2002) and empirical
data from studies such as colorectal cancer (Fearnhead
et al. 2004), HDL cholesterol levels (Cohen et al. 2004),
hypertension (Ji et al. 2008), obesity (Ahituv et al. 2007)
and type 1 diabetes (Nejentsev et al. 2009).
The design of currently available commercial SNP
platforms has been heavily biased towards common SNPs.
GWAS rely on indirect association methods exploiting
local linkage disequilibrium (LD) patterns. Studies per-
formed on large empirical and simulated datasets have
shown that LD-tagging based on HapMap data is robust for
common SNPs, but that performance declines rapidly for
lower frequency variants when common tags are used
(Ahmadi et al. 2005; Zeggini et al. 2005). In addition, rare
variants are notoriously difﬁcult to genotype accurately,
and single-point association analysis of rare variants has
inherently low power given currently available sample
sizes. Indeed, the majority of GWAS exclude low fre-
quency SNPs from further analysis, thus ignoring any
information afforded by the rare variants included in the
arrays. The issue of power to detect association is being
addressed by the development of statistical methods for the
combined analysis of rare variants (Li and Leal 2008;
Morris and Zeggini 2010).
Here we demonstrate, with a proof of principle experi-
ment, that the direct analysis of rare variants (deﬁned here
as MAF B0.05) present on commercially available arrays
can indeed lead to the identiﬁcation of real complex dis-
ease susceptibility signals. We have analysed all rare
variants on the Affymetrix 500K array for the RA branch
of the Wellcome Trust Case Control Consortium (2007)
and have followed up four signals with strong priors for
association with disease. Following extensive checks on
genotype quality and after excluding poorly clustering
variants, we ﬁnd replicating association of rare variation at
the TNFAIP3 locus with RA susceptibility.
Materials and methods
Ethics statement
This study was approved by the North West Multicentre
Research Ethics Committee (MREC 99/8/84), and all
subjects provided informed consent.
Primary scan
Samples, genotyping and quality control
We used data from the RA branch of the WTCCC study
(The Wellcome Trust Case Control Consortium 2007),
genotyped on the Affymetrix GeneChip Human Mapping
500K Array Set. The dataset consisted of 1,860 RA cases
and 2,938 controls, all from the UK, after the exclusion of
samples failing quality control (QC) (The Wellcome Trust
Case Control Consortium 2007). We excluded from further
analysis SNPs failing QC thresholds as described in the
WTCCC study (The Wellcome Trust Case Control Con-
sortium 2007). Brieﬂy, SNPs were excluded based on
deviation from Hardy–Weinberg equilibrium (p\5.7 9
10
-7) or if the study-wise missing data proportion was
[0.05. Additionally, SNPs with a MAF \0.05 were
excluded if the study-wise missing data proportion excee-
ded 0.01. Genotype cluster plot inspection was not possible
at the genome-wide scale, so we inspected the clustering
properties of SNPs within signals of interest after the rare
variant analysis had been carried out.
Rare variant analysis
In order to maximise power to detect association, we fol-
lowed a ‘‘super-locus’’ approach to analysing rare variation
in the GWAS RA data (Li and Leal 2008; Morris and
Zeggini 2010). SNPs with a study-wise MAF\0.05 were
included in the analysis. We deﬁned genic regions genome-
wide based on the coordinates of known genes and (arbi-
trarily) included 50 kilobases (kb) ﬂanking either side of
each gene’s transcriptional start and stop site in an attempt
to include SNPs affecting localised regulatory elements.
For each such region, we collapsed the rare variant allele
counts by assigning each individual a carrier/non-carrier
status based on the presence or absence of rare variant
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123minor alleles (Supplementary Figure 1) (Li and Leal 2008;
Morris and Zeggini 2010). This classiﬁcation system is not
affected by LD, as the number of rare alleles carried by
each individual (the rare allele load) was not taken into
account. This allowed the construction of a simple 2 9 2
contingency table, which we used to test differences in rare
variant minor allele carriage between cases and controls
using the Chi-squared test (or Fisher’s exact test where
necessary). For regions attaining p\10
-4, we also per-
muted case/control status 100,000 times in order to assess
signiﬁcance by means of empirical p values. We used
CCRaVAT software to carry out these analyses (http://
www.sanger.ac.uk/resources/software/ccravat-qutie/). For
the purposes of this study, variants with a MAF B0.05 were
considered low frequency/rare and included in the analysis.
Although this value is arbitrary, it represents a typical
threshold at which SNPs are excluded from further con-
sideration in many GWAS.
Signal prioritisation and quality control
Signals were selected for replication based on the primary
rare variant association scan p value and the existence of
prior evidence to suggest involvement in the susceptibility
to RA. Bins containing only a single rare variant were
excluded from further investigation, as were bins mapping
to the extended MHC region. For the purposes of this
study, the extended MHC was considered to be a 7.6 Mb
region consisting of the extended class I, classical class I,
extended class II, classical class II, and classical class III
subregions. The region is deﬁned by the co-ordinates
Chr6:25,809,997-33,486,772 (NCBI build 36). As low
frequency/rare variants are notoriously difﬁcult to accu-
rately genotype, we examined SNP clustering properties
for all variants contributing to the prioritised signals. To
investigate the inﬂuence of poor quality genotyping on the
performance of the super-locus method we excluded any
SNPs considered to be of low quality, based on clustering,
from the gene region under study and re-analysed.
Replication study
Follow-up patient samples
DNA samples for 3,838 RA cases and 2,719 healthy unre-
latedcontrolsweremadeavailablefromtheUKRheumatoid
Arthritis Genetics (UKRAG) consortium, a collaboration of
six UK rheumatology research groups.
Genotyping and quality control
Low frequency/rare variants contributing to prioritised
association signals in the primary scan were selected for
follow-up. Genotyping was performed using the Sequenom
MassARRAY platform with 10 ng of genomic DNA in
concordance with the manufacturer’s speciﬁcations for the
iPLEX protocol. SNPs rs5029939 and rs7749323 had
already been typed in a subset of the follow-up patient
samples as part of a related study (Orozco et al. 2009). All
Sequenom genotype cluster plots were manually evaluated
to determine satisfactory resolution of clusters. Samples
with a call rate\0.95 and SNPs with a call rate\0.90 were
excluded prior to analysis. Allele counts for all SNPs
mapping to a gene were combined and then compared
between cases and controls using a Fisher’s exact test.
Meta-analysis
We combined individual summary statistics across the
WTCCC RAandUK replication studies using a ﬁxed effects
inverse-variance meta-analysis approach for each genic
region. We also investigated the presence of signiﬁcant het-
erogeneityacross studies, by means of the I
2 and Q statistics.
Results
Primary scan
FollowingQCprocedures,theGWASconsistedof1,860RA
cases and 2,938 healthy controls genotyped for 459,446
SNPs. This dataset included 40,482 SNPs with MAF B0.05
suitable for inclusion in the current analysis. Application of
the super-locus method yielded a total of 22,344 genomic
bins,ofwhich14,536containedatleasttworarevariantsand
mapped outside of the deﬁned MHC region (kGC = 1.09,
Supplementary Figure 2). We identiﬁed 25 gene regions
with a p\10
-4. For the purposes of this study, we priori-
tised four signals for follow-up genotyping that emerged
from two distinct chromosomal regions. This selection was
basedontheirrarevariantanalysispvalueandpriorevidence
to support disease association. Firstly, we selected SNPs
from three gene regions mapping to chromosome 17q24;
ACE, CYB561, and PRKCA (p = 6.0 9 10
-5, p = 2.7 9
10
-5andp = 0.0012respectively).Thisregionisimplicated
insusceptibilitytoRAbypreviousevidencefromhumanand
animal linkage studies and is of particular interest to our
research group (Backdahl et al. 2008; Barton et al. 2001;
Jawaheer et al. 2001). To date, no common susceptibility
variants that could explain the observed linkage signal have
been discovered in this region, and this could be attributable
to the presence of associated rare variants. The second can-
didate locus was the TNFAIP3 gene (p = 4.2 9 10
-5), a
known RA-associated locus with evidence for allelic heter-
ogeneity (Orozco et al. 2009; Plenge et al. 2007; Thomson
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123et al. 2007). These four bins comprise a total of 27 unique
SNPs (due to overlap the ACE and CYB561 gene regions
share two SNPs). Individual SNP genotype data and asso-
ciation results are reported in Supplementary Table 1. For
the purposes of evaluating data quality we examined the
clustering properties of rare variants residing in the associ-
atedgeneregionsandidentiﬁedsixSNPswithunsatisfactory
clustering. Re-analysis of the data after excluding the badly
clustering variants did not alter the results for the TNFAIP3
and PRKCA loci qualitatively, but did affect signiﬁcance at
the other two genes (Table 1; Supplementary Table 2).
Replication study
We attempted to genotype all 27 SNPs from the four bins,
regardless of clustering results, in an independent dataset
consisting of 3,355 cases and 2,427 controls after QC ﬁl-
tering. Three SNPs failed assay multiplexing and 24 SNPs
were successfully genotyped. SNPs were partitioned into
appropriategeneregionsandproportionsofcarriersandnon-
carrierswerecomparedbetweenthecaseandcontrolgroups.
Evidence to support rare variant association with RA in the
TNFAIP3 gene was further substantiated (p = 0.03)
(Table 1). No evidence was found to support association in
the three genes mapping to the chr17 candidate region.
Meta-analysis
Meta-analysis across the discovery and replication datasets
revealed stronger evidence for association of low fre-
quency variants in TNFAIP3 with RA (combined
p = 6.6 9 10
-6; OR 1.27[1.14:1.40]) (Table 1). The
direction of association indicated an over-representation of
rare variant minor alleles in cases compared to controls.
Discussion
To date GWAS have concentrated on the investigation of
common variation therefore discarding a signiﬁcant
proportion of data already collected, since a common QC
criterion is the exclusion of SNPs with low MAF. The
evidence presented here highlights the potential importance
of investigating low frequency variant data from com-
mercial SNP arrays. It should be noted that the primary
purpose of these analyses is signal detection and not
accurate effect estimation. The application of a rare variant
analysis method (Li and Leal 2008; Morris and Zeggini
2010), which accumulates information from multiple rare
SNP alleles within a genic region, identiﬁed an association
between RA and the TNFAIP3 gene.
Multiple independent RA associations have previously
been reported at the TNFAIP3 locus. The most convincing
evidence for association to rare variants in this region
comes from the meta-analysis described here (p = 6.6 9
10
-6). Association to the 6q23 region was originally
identiﬁed for common variants by two independent GWAS
(Plenge et al. 2007; The Wellcome Trust Case Control
Consortium 2007). The WTCCC RA GWAS identiﬁed a
common RA risk variant[180 kb away from the TNFAIP3
gene, which was replicated in a UK study (Thomson et al.
2007). This ﬁnding prompted a ﬁne mapping experiment
covering the intergenic region containing the index asso-
ciation and the TNFAIP3 gene across *7,000 individuals,
identifying an independent association at rs5029937 (MAF
*0.04) in intron 2 of TNFAIP3 (Orozco et al. 2009). The
evidence for multiple independent effects in the TNFAIP3
gene region make this a compelling candidate for re-
sequencing.
Application of the super-locus approach using the ori-
ginal WTCCC data alone (2,000 cases, 3,000 controls)
prior to the ﬁne-mapping project would have directed
attention to this signal obviating the need for time-con-
suming and costly region-wide ﬁne-mapping. LD between
the low frequency variants in the TNFAIP3 gene region
reported here and the intergenic SNPs, previously shown to
be associated with RA, is minimal (r
2\0.04). However,
there is strong LD between two SNPs from the super-locus
analysed here and rs5029937 (rs7749323 r
2 = 0.91 and
rs5029939 r
2 = 0.97). Our results highlight the potential
strength of analysing lower frequency/rare variants in a
Table 1 Results for the four rare variant gene bins
Locus WTCCC Replication Meta-analysis
n SNPs OR p value n SNPs OR p value OR p value I
2
ACE 2 1.27 (0.59:2.71) 0.54 2 2.00 (0.88:4.52) 0.09 1.59 (0.92:2.75) 0.098 0
PRKCA 11 1.27 (1.09:1.48) 1.54E-03 10 1.01 (0.88:1.16) 0.85 1.12 (1.02:1.24) 0.023 79.1
CYB561 2 1.59 (0.69:3.67) 0.28 2 1.65 (0.83:3.28) 0.15 1.63 (0.96:2.76) 0.072 0
TNFAIP3 7 1.39 (1.20:1.62) 1.24E-05 6 1.16 (1.01:1.34) 0.03 1.27 (1.14:1.40) 6.60E-06 66
OR odds ratio (95% conﬁdence intervals in parentheses); n number
Results presented here are following exclusion of the six SNPs identiﬁed as having poor clustering properties
630 Hum Genet (2010) 128:627–633
123complementary approach to the primary GWAS of com-
mon variants.
The study of low frequency/rare variants from commer-
cial SNP arrays islimited by a number of factors. Firstly, the
arrays contain only a small proportion of the low MAF
variants that actually exist; this is due to the array design
being motivated by the detection of common susceptibility
variants. The gold standard strategy for investigating lower
frequency/rare variants will be the use of sequencing data,
capturing a much higher proportion of genetic variation
(Morris and Zeggini 2010). However, in spite of the rapid
advances in sequencing technology, this approach is often
limited by economic constraints when considering large
sample sizes. The method applied here utilises existing data
that are generally discarded in GWAS. It therefore increases
the amount of available data that are analysed and comes at
no additional cost to the researcher. Collapsing methods are
also very ﬂexible in their application. In the study presented
here we have focused on gene-centric bins, but this could be
expanded to include bins based on coordinates of known
conserved non-coding regions or functional pathways as the
functional unit for analysis.
Secondly, the genotype quality of rare variants typed on
GWAS platforms tends to be low, mainly driven by poor
automated clustering and genotype calling. This limitation
affects both single-point and collapsing methods and
necessitates stringent and exhaustive inspection of cluster
plots in association signals of interest. The potential for
confounding is demonstrated in our study by the effect of
excluding poorly clustering SNPs in the ACE and CYB561
gene regions. These two bins were no longer statistically
signiﬁcant upon removal of poor quality SNPs, thus high-
lighting the potential for inﬂated false positive rates in the
absence of stringent quality assurance when dealing with
low frequency SNP data. In addition, it is highly likely that
bins containing only a few SNPs have an increased sensi-
tivity to such artefacts. Genotype calling algorithms ﬁne-
tuned for rare variant clustering have recently been
developed and hold the promise of helping to overcome
many of these issues.
Thirdly, collapsing methods can be limited by the
properties of the component variants. For example, they
have been shown to be sensitive to the inclusion of neutral
alleles, whose presence reduces power. Ideally, each of the
bins would only contain putatively functional variants,
which could be achieved by the use of bioinformatics tools.
However, the accuracy of such tools is currently limited and
the reduction of power is greater when true functional SNPs
are excluded compared to the inclusion of functionally
neutral SNPs (Li and Leal 2008). Additionally, it is con-
ceivable that bins could contain variants with diverse
effects, where the presence of both protective and risk
alleles would confound the analysis. Rare variant collapsing
methods are being further developed and extended to
account for direction of effect, probability that a variant be
functional, and genotype or sequence call uncertainty.
Finally, the phenotype under investigation could
strongly dictate the success of identifying novel, rare dis-
ease-related variants. It could be argued that late-onset
diseases, such as RA, are less likely to be inﬂuenced by a
contribution from rare variants. However, the underlying
genetic architecture of the disease is yet to be fully eluci-
dated; collapsing methods represent one strategy that can
help address this question.
Despite these limitations, our results illustrate that col-
lapsing methods represent a strategy with the potential for
identifying novel variants at no additional cost to the
researcher, thus maximising return from costly primary
GWAS. Applying this approach to existing SNP array data
would have expedited the identiﬁcation of the TNFAIP3
intron 2 SNP association with RA. We advocate the
application of this method in conjunction with primary
GWAS for complex diseases, but also suggest extreme
caution with the interpretation of promising signals, which
need to be scrutinised for genotype quality. Additionally,
collapsing methods hold great promise for the future with
the application to sequencing data.
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